]>
IRCT20141209020258N165 IRCT 2021-09-10 Arak University of Medical Sciences Evaluation of the effect of L-Carnitine on patients with moderate to severe condition of Covid-19 ‎admitted to critical care unit Evaluation of the effect of L-Carnitine on patients with moderate to severe condition of Covid-19 ‎admitted to critical care unit 2021-09-23 anticipated 64 Complete https://irct.ir/trial/58524 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple individual randomization with random allocation with envelopes in 3 groups A and B and C. In this method, we selected a number of cards or letters as an intervention group and the same ‎number of cards for the control group, then the cards were merged. One card was taken out and its ‎allocation was registered and the card was returned to the other cards after leaving. Then the cards ‎are merged again and we remove another card. This process continues to reach a random sequence ‎according to sample size, Blinding description: In terms of patient blindness, the complementary intern does not know the groupings, and general anesthesia and drug injections are performed by an anesthesiologist. Outcome assessor and data analyzer and participant are blind (double blind). Outcome assessor and data analyzer and participant don't aware from grouping. The intern is unaware of the drugs prescribed in each group and the anesthesiologist prepares the drugs and provides them to the intern. Also, the patients do not know about their group. 3 With Quid-19 with moderate disease severity. Intervention 1: Intervention group: In addition to routine treatment, patients will receive 1 gram of L-carnitine supplement per day (Karen 1000 mg L-carnitine tablets) for 7 days. Intervention 2: Control group: Routine treatment of patients receiving Covid-19 based on protocol with placebo. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public Dr Hesamedin Modir
Valiasr Hospital, Valiasr squre, Shahid Shirodi street
Arak Iran (Islamic Republic of) 3814957558 +98 86 3222 2003 modir.he@gmail.com Arak University of Medical Sciences scientific Dr Behnam Mahmodie
Valiasr Hospital, Valiasr squre, Shahid Shirodi street
Arak Iran (Islamic Republic of) 3814957558 +98 86 3222 2003 mahmodie@arakmu.ac.ir Arak University of Medical Sciences Iran (Islamic Republic of) Suffering Covid-19 without intubation Apache less than 25 28 to 75 years Absence of acute asthma Absence of acute pulmonary hemorrhage Absence of lung tumor Absence of untreated pneumothorax Do not take anticoagulants (coumadin group such as warfarin) No history of kidney or liver disease No diabetes (because of the risk of hypoglycemia) No history of seizures 28 years 75 years Both Death Patient dissatisfaction with attending the study for any reason U07.1 COVID-19, virus identified Treatment - Drugs Treatment - Drugs Intervention group: In addition to routine treatment, patients will receive 1 gram of L-carnitine supplement per day (Karen 1000 mg L-carnitine tablets) for 7 days. Control group: Routine treatment of patients receiving Covid-19 based on protocol with placebo. Intravenous blood gas samples. Timepoint: Daily. Method of measurement: Intravenous blood samples. Disease severity. Timepoint: Daily. Method of measurement: Checklist Apache II. Length of hospital stay. Timepoint: End of study. Method of measurement: Patient file. Mortality. Timepoint: End of study. Method of measurement: Patient file. Arak University of Medical Sciences Approved 2021-08-08 Ethics comittee of Arak University of Medical Sciences Ethics comittee, Research center, Payambar Azam complex, Basij squre ,Sardasht,Arak Arak Markazi Iran (Islamic Republic of)